AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20118150 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple group
Number of subjects: 90
Study 20118150 — intervention group
Group type: EXPERIMENTAL
Intervention: High maintenance dose (MD) group
Number of subjects: 90
Study 20118150 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 90
Study 18198640 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI), intravenously dripped once daily, starting 3 days before radiotherapy to 1 week after the end of it.
Number of subjects: 58
Study 18198640 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (Control group).
Number of subjects: 58
Study 18198640 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI).
Number of subjects: 58
Study 16305269 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic treatment group (supervised exercise, individualized manual therapy, home exercise program)
Number of subjects: 134
Study 16305269 — intervention group
Group type: COMPARATOR
Intervention: Home exercise group (home exercise program)
Number of subjects: 134
Study 16305269 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 134
Study 16305269 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic treatment group
Number of subjects: 134
Study 12218500 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5% (LP)
Number of subjects: 96
Study 9468746 — intervention group
Group type: EXPERIMENTAL
Intervention: BT + PSA
Number of subjects: 108
Study 9468746 — intervention group
Group type: EXPERIMENTAL
Intervention: BT
Number of subjects: 108
Study 9468746 — intervention group
Group type: COMPARATOR
Intervention: WLE
Number of subjects: 108
Study 7637923 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking alone
Number of subjects: 181
Study 7637923 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt restriction alone
Number of subjects: 181
Study 7637923 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (brisk walking + salt restriction)
Number of subjects: 181
Study 7637923 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 181
Study 2575450 — intervention group
Group type: EXPERIMENTAL
Intervention: trans-Dihydrolisuride (terguride)
Number of subjects: 10
Study 31562105 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft haptic finger‐worn wearable device using TCP actuators
Number of subjects: 14
Study 31562105 — intervention group
Group type: COMPARATOR
Intervention: Vibrotactile feedback system
Number of subjects: 14
Study 25972128 — intervention group
Group type: EXPERIMENTAL
Intervention: BE‐ACTIV intervention
Number of subjects: 18
Study 25972128 — intervention group
Group type: COMPARATOR
Intervention: Walking and Talking intervention
Number of subjects: 18
Study 25781654 — intervention group
Group type: COMPARATOR
Intervention: BCAA infusion (N = 5) during insulin infusion at 40 mU/m2/min
Number of subjects: 17
Study 25781654 — intervention group
Group type: COMPARATOR
Intervention: BCAA infusion (N = 4) during insulin infusion at 80 mU/m2/min
Number of subjects: 17
Study 23953658 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 315
Study 23953658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 23953658 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 315
Study 23953658 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 315
Study 22030938 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 1% gel (DSG), applied 4 g to 1 or both knees 4 times daily for 9 to 12 months.
Number of subjects: 583
Study 22030938 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 1% gel (DSG).
Number of subjects: 583
Study 18390970 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide, doxorubicin, and fluorouracil (CAF) chemotherapy
Number of subjects: 1572
Study 18390970 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose CAF chemotherapy
Number of subjects: 1572
Study 16622437 — intervention group
Group type: COMPARATOR
Intervention: General practitioners follow-up
Number of subjects: 203
Study 16622437 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons follow-up
Number of subjects: 203
Study 14569523 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% mandibular advancement (MA)
Number of subjects: 86
Study 11113048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis-dependent renal failure patients
Number of subjects: 279
Study 11113048 — intervention group
Group type: COMPARATOR
Intervention: Other CABG patients (control group)
Number of subjects: 279
Study 9026840 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin (20 mg/day)
Number of subjects: 21
Study 9026840 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate (400 mg/day)
Number of subjects: 21
Study 9026840 — intervention group
Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 21
Study 1620456 — intervention group
Group type: EXPERIMENTAL
Intervention: IgIv 0.2 g/kg on day 0, day 2, day 5, day 12
Number of subjects: 64
Study 1620456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 6465622 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized terbutaline
Number of subjects: 0
Study 6465622 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous epinephrine
Number of subjects: 0
Study 30789207 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT-based intervention
Number of subjects: 230
Study 30789207 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 230
Study 30231894 — intervention group
Group type: EXPERIMENTAL
Intervention: Training via locally made educational videos on low-cost Android tablets
Number of subjects: 129
Study 30231894 — intervention group
Group type: COMPARATOR
Intervention: Traditional training through a 1-day in-person workshop
Number of subjects: 129
Study 26900961 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (2 mA for 30 minutes)
Number of subjects: 120
Study 26900961 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 120
Study 24152086 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate (200 μg for 7 days, then 800 μg for 7 days from a dry powder inhaler)
Number of subjects: 80
Study 24152086 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluticasone furoate (250 μg infusion)
Number of subjects: 80
Study 24152086 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate (200 μg)
Number of subjects: 80
Study 24152086 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate (200 μg and 800 μg)
Number of subjects: 80
Study 22044753 — intervention group
Group type: EXPERIMENTAL
Intervention: catumaxomab
Number of subjects: 258
Study 22044753 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 258
Study 20655662 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment+cognitive‐behavioral skills training (STD+CBT)
Number of subjects: 101
Study 20655662 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (STD)
Number of subjects: 101
Study 16217588 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day (RLX60)
Number of subjects: 0
Study 16217588 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day and 150 mg/day (RLX120/150)
Number of subjects: 0
Study 14663300 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity intervention group (A) - lifestyle counselling and group-based counselling
Number of subjects: 12816
Study 14663300 — intervention group
Group type: COMPARATOR
Intervention: Low intensity intervention group (B) - referred to GP
Number of subjects: 12816
Study 14663300 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - followed by questionnaire
Number of subjects: 12816
Study 14733645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m2) plus Gemcitabine (1000 mg/m2) plus Vinorelbine (25 mg/m2) (PGV)
Number of subjects: 180
Study 14733645 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (100 mg/m2) plus Gemcitabine (1000 mg/m2) (PG)
Number of subjects: 180
Study 14733645 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (120 mg/m2) plus Vinorelbine (30 mg/m2/week) (PV)
Number of subjects: 180
Study 9196598 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram/kg body weight GHRH bolus at 0 minutes (group I)
Number of subjects: 36
Study 9196598 — intervention group
Group type: EXPERIMENTAL
Intervention: Two consecutive 1 microgram/kg body weight GHRH boluses at 0 and 120 minutes (group II)
Number of subjects: 36
Study 9196598 — intervention group
Group type: EXPERIMENTAL
Intervention: Two consecutive 1 microgram/kg body weight hexarelin boluses at 0 and 120 minutes (group II)
Number of subjects: 36
Study 14621718 — intervention group
Group type: EXPERIMENTAL
Intervention: Four different immunosuppressive regimens
Number of subjects: 0
Study 14621718 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment groups
Number of subjects: 0
Study 3902413 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ampicillin (1 g in each surgical wound)
Number of subjects: 203
Study 3902413 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics (ampicillin 1 g X 3 and metronidazole 0.5 g X 3)
Number of subjects: 203
Study 31881991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led therapeutic carbohydrate restricted (Pharm-TCR) diet
Number of subjects: 200
Study 31881991 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based treatment as usual (TAU)
Number of subjects: 200
Study 28969887 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (1 × 10^8 colony forming unit)
Number of subjects: 0
Study 28969887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26291594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intracoronary N-acetylcysteine (100 mg/kg bolus, followed by 10 mg·kg⁻¹·h⁻¹ for 12 hours)
Number of subjects: 100
Study 26291594 — intervention group
Group type: COMPARATOR
Intervention: Dextrose solution (control)
Number of subjects: 100
Study 26291594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intracoronary N-acetylcysteine
Number of subjects: 100
Study 24044373 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) training program over 12 weeks
Number of subjects: 0
Study 24044373 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 22920158 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 351
Study 22920158 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary intervention
Number of subjects: 351
Study 20719315 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsion adapter
Number of subjects: 10
Study 20719315 — intervention group
Group type: COMPARATOR
Intervention: Rigid adapter
Number of subjects: 10
Study 17376183 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal glucocorticoid (betamethasone)
Number of subjects: 228
Study 17376183 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal glucocorticoid (long exposure)
Number of subjects: 228
Study 17376183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 16597681 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients (n = 24)
Number of subjects: 91
Study 16597681 — intervention group
Group type: COMPARATOR
Intervention: Uric acid stone formers (UASF; n = 8)
Number of subjects: 91
Study 16597681 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers (NV; n = 59)
Number of subjects: 91
Study 12631373 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin 7.5% solution
Number of subjects: 40
Study 12631373 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose solutions
Number of subjects: 40
Study 10759661 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride (TCl, 20 mg twice daily)
Number of subjects: 208
Study 10759661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 8838434 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg caroverine
Number of subjects: 16
Study 8838434 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg caroverine
Number of subjects: 16
Study 8838434 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg caroverine
Number of subjects: 16
Study 8838434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1349494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (2 x 10 mg daily for 3 days)
Number of subjects: 12
Study 1349494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2416297 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride (norepinephrine uptake inhibitor)
Number of subjects: 0
Study 2416297 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimeldine hydrochloride (serotonin uptake inhibitor)
Number of subjects: 0
Study 2416297 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorgyline (selective monoamine oxidase type A inhibitor)
Number of subjects: 0
Study 30941442 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal massage and pelvic floor muscle training (PFMT) with educational program
Number of subjects: 200
Study 30941442 — intervention group
Group type: COMPARATOR
Intervention: Prevention education program only
Number of subjects: 200
Study 30571502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 21162
Study 27926472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweetened beverage intake >2 servings daily (6% of participants)
Number of subjects: 1864
Study 27926472 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 200 mL daily serving of sweetened beverages
Number of subjects: 1864
Study 27926472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages
Number of subjects: 1864
Study 27926472 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificially sweetened beverages
Number of subjects: 1864
Study 27926472 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sweetened beverage intake
Number of subjects: 1864
Study 27926472 — intervention group
Group type: EXPERIMENTAL
Intervention: High consumers of sweetened beverages in type 2 diabetes
Number of subjects: 1864
Study 27926472 — intervention group
Group type: EXPERIMENTAL
Intervention: High consumers of sweetened beverages in LADA
Number of subjects: 1864
Study 25721356 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Prednisone plus Low-Dose Cyclophosphamide
Number of subjects: 33
Study 25721356 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus Prednisone
Number of subjects: 33
Study 22525957 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic Interview Schedule for Children (DISC)
Number of subjects: 646
Study 22525957 — intervention group
Group type: EXPERIMENTAL
Intervention: Child and Adolescent Psychiatric Assessment (CAPA)
Number of subjects: 646
Study 22525957 — intervention group
Group type: EXPERIMENTAL
Intervention: Development and Well-Being Assessment (DAWBA)
Number of subjects: 646
Study 22525957 — intervention group
Group type: EXPERIMENTAL
Intervention: DAWBA
Number of subjects: 646
Study 22525957 — intervention group
Group type: COMPARATOR
Intervention: DISC and CAPA
Number of subjects: 646
Study 19717485 — intervention group
Group type: EXPERIMENTAL
Intervention: In‐DTPA
Number of subjects: 21
Study 19717485 — intervention group
Group type: COMPARATOR
Intervention: Tc‐SC
Number of subjects: 21
Study 18301949 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic restorative proctocolectomy
Number of subjects: 35
Study 16291160 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective delivery at 36 weeks
Number of subjects: 42
Study 16291160 — intervention group
Group type: COMPARATOR
Intervention: Await spontaneous labor
Number of subjects: 42
Study 12183217 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 18
Study 12183217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10337292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac-Fil
Number of subjects: 34
Study 10337292 — intervention group
Group type: EXPERIMENTAL
Intervention: Photac-Fil
Number of subjects: 34
Study 9026175 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (transdermal estrogen patch)
Number of subjects: 41
Study 1672137 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 7
Study 1672137 — intervention group
Group type: COMPARATOR
Intervention: Psoralen + UVA (PUVA) therapy
Number of subjects: 7
Study 6752871 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen (1200 mg, 400 mg t.i.d.)
Number of subjects: 134
Study 6752871 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg, 50 mg t.i.d.)
Number of subjects: 134
Study 6752871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 31903802 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 exposure (10 µg/m3 increase in 1-month mean)
Number of subjects: 165675
Study 31903802 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter-duration PM10 exposures
Number of subjects: 165675
Study 31209792 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-102
Number of subjects: 84
Study 28350181 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter oxygen group with Hb ≤ 70 g/L
Number of subjects: 59
Study 28350181 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter oxygen group with 71 g/L ≤ Hb ≤ 90 g/L
Number of subjects: 59
Study 28350181 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-assisted breathing group with 71 g/L ≤ Hb ≤ 90 g/L
Number of subjects: 59
Study 28350181 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-assisted breathing group with Hb ≥ 91 g/L
Number of subjects: 59
Study 28350181 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 71 g/L ≤ Hb ≤ 90 g/L subgroups
Number of subjects: 59
Study 26228328 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-continuous technique for mitral valve replacement
Number of subjects: 100
Study 26228328 — intervention group
Group type: COMPARATOR
Intervention: Interrupted suture technique for mitral valve replacement
Number of subjects: 100
Study 23132045 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 10
Study 23132045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 10
Study 21684428 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic H1N1 live attenuated influenza vaccine (LAIV)
Number of subjects: 0
Study 21684428 — intervention group
Group type: COMPARATOR
Intervention: HAI assay
Number of subjects: 0
Study 18443134 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (fish oil; Omegaven 10%; 0.15 - 0.2 g/kg/d)
Number of subjects: 40
Study 18443134 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (Lipovenos 20%)
Number of subjects: 40
Study 17194229 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined uphill-downhill training
Number of subjects: 35
Study 17194229 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill training
Number of subjects: 35
Study 17194229 — intervention group
Group type: COMPARATOR
Intervention: Horizontal training
Number of subjects: 35
Study 17194229 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 12544374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal AVP (2 x 20 IU) for 10 weeks
Number of subjects: 26
Study 12544374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11043125 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative treatment
Number of subjects: 370
Study 11043125 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 370
Study 11043125 — intervention group
Group type: COMPARATOR
Intervention: Both operative and non-operative treatment
Number of subjects: 370
Study 11043125 — intervention group
Group type: COMPARATOR
Intervention: Retrospective studies (both operative and conservative therapy)
Number of subjects: 370
Study 11043125 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 370
Study 12056098 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane at 500 mg/m2 commencing at the seventh cycle of treatment
Number of subjects: 0
Study 1529875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan 5 mg daily
Number of subjects: 198
Study 1529875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 3903782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline
Number of subjects: 20
Study 3903782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31144762 — intervention group
Group type: EXPERIMENTAL
Intervention: Suplatast tosilate
Number of subjects: 0
Study 31144762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29297943 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrapping in sandwiched sheets (two prewarmed sheets with a layer of newspaper)
Number of subjects: 100
Study 29297943 — intervention group
Group type: COMPARATOR
Intervention: Control group (two prewarmed sheets without a layer of newspaper)
Number of subjects: 100
Study 27423044 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 0.5 mg
Number of subjects: 0
Study 27423044 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 0.25 mg
Number of subjects: 0
Study 27423044 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 0.375 mg
Number of subjects: 0
Study 27423044 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast N-oxide
Number of subjects: 0
Study 25669214 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB)
Number of subjects: 80
Study 25669214 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (STD)
Number of subjects: 80
Study 23983460 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week exercise intervention
Number of subjects: 378
Study 23983460 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 378
Study 21906396 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of Care Technologies (POCT)
Number of subjects: 239